arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BIOCRYST PHARMACEUTICALS INC

BCRX
$8.55 ▼ -0.22 (-2.56%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
62
Health
Fair
Moderately Bullish
auto_awesome

Analytical Summary

BIOCRYST PHARMACEUTICALS INC demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $2.2B
Dividend Yield —
Revenue Growth 33.6% ↗
Op. Margin 45.1% ↗
ROIC -164.9% ↘
FCF / Share $0.41 ↗
Trailing P/E 27.6x
Price / Book —
FCF Yield 4.8%
Debt / Equity -0.87
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$218.25M
↑ +33.6% —
Net Income Profit after all expenses
$-721.81M
— 0.0% —
Operating Margin Operating profit as % of sales
45.1%
↑ +110.1% 93th
FCF / Share Free cash flow per share
$0.41
↑ +260.8% —
Long-Term Debt Long-term obligations
$395.40M
— +0.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
93
Returns
1
Financial Health ↑
91
Cash Quality ↑
76

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters